Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NTLA Stock Forecast 2026-2027
$13.02
Current Price
$1.82B
Market Cap
Buy 11
Hold 8
Sell 2
Wall St Analyst Ratings
Distance to NTLA Price Targets
+629.6%
To High Target of $95.00
+38.2%
To Median Target of $18.00
-38.6%
To Low Target of $8.00
NTLA Price Momentum
-25.3%
1 Week Change
+7.5%
1 Month Change
+9.0%
1 Year Change
+44.8%
Year-to-Date Change
-53.9%
From 52W High of $28.25
+63.8%
From 52W Low of $7.95
📊 TOP ANALYST CALLS
Did NTLA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Intellia is one of their latest high-conviction picks.
Latest NTLA Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, NTLA has a bullish consensus with a median price target of $18.00 (ranging from $8.00 to $95.00). The overall analyst rating is Buy (7.6/10). Currently trading at $13.02, the median forecast implies a 38.2% upside. This outlook is supported by 11 Buy, 8 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NTLA Analyst Ratings
11
Buy
8
Hold
2
Sell
NTLA Price Target Range
Low
$8.00
Average
$18.00
High
$95.00
Current: $13.02
Latest NTLA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NTLA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 10, 2026 | Wedbush | David Nierengarten | Neutral | Maintains | $17.00 |
| Jun 16, 2026 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $49.00 |
| Jun 15, 2026 | Citizens | Silvan Turkcan | Market Outperform | Reiterates | $30.00 |
| Jun 15, 2026 | Wedbush | David Nierengarten | Neutral | Reiterates | $12.00 |
| Jun 15, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Reiterates | $25.00 |
| May 13, 2026 | Bernstein | Market Perform | Maintains | $N/A | |
| May 13, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 12, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 12, 2026 | Wedbush | Neutral | Reiterates | $N/A | |
| Apr 28, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Apr 28, 2026 | Goldman Sachs | Sell | Maintains | $N/A | |
| Apr 28, 2026 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Apr 28, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Apr 27, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Apr 27, 2026 | Baird | Neutral | Maintains | $N/A | |
| Mar 4, 2026 | Jones Trading | Buy | Upgrade | $N/A | |
| Mar 3, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 3, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Mar 3, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Mar 3, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A |
Intellia Therapeutics Inc. (NTLA) Competitors
The following stocks are similar to Intellia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Intellia Therapeutics Inc. (NTLA) Financial Data
Intellia Therapeutics Inc. has a market capitalization of $1.82B with a P/E ratio of -3.4x. The company generates $66.09M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -9.5% quarter-over-quarter, while maintaining an operating margin of -668.1% and return on equity of -56.3%.
Valuation Metrics
Market Cap
$1.82B
Enterprise Value
$1.69B
P/E Ratio
-3.4x
PEG Ratio
0.1x
Price/Sales
30.1x
Growth & Margins
Revenue Growth (YoY)
-9.5%
Gross Margin
N/A
Operating Margin
-668.1%
Net Margin
0.0%
EPS Growth
-9.5%
Financial Health
Cash/Price Ratio
+20.7%
Current Ratio
6.1x
Debt/Equity
13.0x
ROE
-56.3%
ROA
-30.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Intellia Therapeutics Inc. (NTLA) Business Model
About Intellia Therapeutics Inc.
What They Do
Develops genome editing therapies using CRISPR technology.
Business Model
The company operates a clinical-stage biotechnology model, focusing on developing genome editing therapies for genetically defined diseases. It generates revenue through collaborations with major pharmaceutical partners, which helps in the advancement and potential commercialization of its innovative treatments.
Additional Information
Intellia Therapeutics targets conditions with significant unmet medical needs, such as ATTR amyloidosis and sickle cell disease. The company is based in Cambridge, Massachusetts, a prominent area for life sciences and biotechnology innovation, positioning it well within the industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
377
CEO
Dr. John M. Leonard M.D.
Country
United States
IPO Year
2016
Website
www.intelliatx.comIntellia Therapeutics Inc. (NTLA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
Jul 09, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Intellia's stock rose 38% in a month, driven by positive phase III lonvo-z data and advancements in its pipeline, increasing investor confidence.
Why It Matters
Intellia's 38% gain signals strong investor confidence driven by positive trial results and pipeline advancements, indicating potential for future growth and profitability.
Source: Zacks Investment Research
Market Sentiment:
Positive
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
6 days ago
Quick Summary
A new CRISPR molecule has been developed that can target and destroy cells expressing specific signals, enhancing gene-editing capabilities for advanced medicine development.
Why It Matters
The new CRISPR molecule could enhance targeted therapies, potentially leading to breakthrough treatments and increased market opportunities in biotech, boosting investor interest in gene-editing companies.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Intellia Therapeutics awarded inducement grants to 13 new employees under its 2024 Inducement Plan on July 1, 2026, as part of its recruitment strategy.
Why It Matters
Intellia's employee inducement grants signal growth and investment in talent, indicating potential for innovation and future advancements, which can positively influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Intellia Therapeutics has successfully completed a phase 3 study for a leading candidate and is advancing another late-stage asset with greater commercial potential.
Why It Matters
Intellia Therapeutics' successful phase 3 study boosts investor confidence, suggesting potential revenue growth and increased market value, especially with another promising late-stage asset.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Late June short-interest data indicates extreme bearish positioning among mid- and large-cap stocks, potentially leading to significant market volatility if sentiment changes.
Why It Matters
High short interest in mid- and large-cap stocks indicates potential for significant price volatility. A shift in market sentiment could lead to rapid gains or losses, impacting investor strategies.
Source: Benzinga
Market Sentiment:
Neutral
Quick Summary
Intellia Therapeutics is advancing CRISPR gene editing therapies through a partnership with Regeneron. Omeros has gained FDA approval for Yartemlea and secured a deal with Novo Nordisk.
Why It Matters
Intellia's partnership with Regeneron enhances its gene editing advancements, potentially boosting stock value. Omeros' FDA approval and deal with Novo Nordisk indicate strong market positioning.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About NTLA Stock
What is Intellia Therapeutics Inc.'s (NTLA) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Intellia Therapeutics Inc. (NTLA) has a median price target of $18.00. The highest price target is $95.00 and the lowest is $8.00.
Is NTLA stock a good investment in 2027?
According to current analyst ratings, NTLA has 11 Buy ratings, 8 Hold ratings, and 2 Sell ratings. The stock is currently trading at $13.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NTLA stock?
Wall Street analysts predict NTLA stock could reach $18.00 in the next 12 months. This represents a 38.2% increase from the current price of $13.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Intellia Therapeutics Inc.'s business model?
The company operates a clinical-stage biotechnology model, focusing on developing genome editing therapies for genetically defined diseases. It generates revenue through collaborations with major pharmaceutical partners, which helps in the advancement and potential commercialization of its innovative treatments.
What is the highest forecasted price for NTLA Intellia Therapeutics Inc.?
The highest price target for NTLA is $95.00 from at , which represents a 629.6% increase from the current price of $13.02.
What is the lowest forecasted price for NTLA Intellia Therapeutics Inc.?
The lowest price target for NTLA is $8.00 from at , which represents a -38.6% decrease from the current price of $13.02.
What is the overall NTLA consensus from analysts for Intellia Therapeutics Inc.?
The overall analyst consensus for NTLA is bullish. Out of 5 Wall Street analysts, 11 rate it as Buy, 8 as Hold, and 2 as Sell, with a median price target of $18.00.
How accurate are NTLA stock price projections?
Stock price projections, including those for Intellia Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 1:14 PM UTC